Successful long-term treatment with the bradykinin B2 receptor antagonist icatibant in a patient with hereditary angioedema.
Hereditary angioedema (HAE) is a rare, autosomal dominant disorder caused by a C1-esterase inhibitor (C1-INH) deficiency (type 1) or qualitative defect (type 2). It is characterized by recurrent subcutaneous or submucosal edema attacks in various organs with a frequency from a few attacks to over one hundred attacks per year.
We report on the treatment of 141 attacks in a patient with hereditary angioedema with the bradykinin B2 receptor antagonist icatibant.
During the entire observation period, efficacy of icatibant was maintained and not altered due to repeated administrations. No systemic or cardiovascular side affects were observed.
In the present case, icatibant proved to be an effective and safe drug for the symptomatic treatment of acute HAE attacks. Its efficacy was not impaired by repeated administrations over a three-year period in this patient.
Department of Otorhinolaryngology, University Hospital Essen, University Duisburg, Essen, Germany. email@example.com
SourceInternational journal of dermatology 50:10 2011 Oct pg 1294-5
MeSHAnti-Inflammatory Agents, Non-Steroidal
Clinical Trials, Phase III as Topic
Drug Administration Schedule
Hereditary Angioedema Types I and II
Receptor, Bradykinin B2
Pub Type(s)Case Reports
Research Support, Non-U.S. Gov't